{{Drugbox
| IUPAC_name = 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethylpyrimidine-2,4(1''H'',3''H'')-dione
| image = Urapidil.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|urapidil}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 34661-75-1
| CAS_supplemental = <br />64887-14-5 ([[Hydrochloride|HCl]])
| ATC_prefix = C02
| ATC_suffix = CA06
| PubChem = 5639
| ChemSpiderID = 5437
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A78GF17HJS
| ChEMBL = 279229

<!--Chemical data-->
| C=20 | H=29 | N=5 | O=3 
| molecular_weight = 387.48 g/mol
| smiles = O=C1\C=C(/N(C(=O)N1C)C)NCCCN3CCN(c2ccccc2OC)CC3
}}

'''Urapidil''' is a [[sympatholytic]] [[antihypertensive]] [[drug]]. It acts as an [[alpha-1 adrenoceptor|α<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonist]] and as an [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[agonist]].<ref name="pmid1855130">{{cite journal |author=Ramage AG |title=The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors |journal=Br. J. Pharmacol. |volume=102 |issue=4 |pages=998–1002 |date=April 1991 |pmid=1855130 |pmc=1917978 |doi= 10.1111/j.1476-5381.1991.tb12290.x|url=}}</ref> Although an initial report suggested that urapidil was also an [[alpha-2 adrenoceptor|α<sub>2</sub>-adrenoceptor]] [[agonist]],<ref name="pmid228944">{{cite journal|author=Eltze M |title=Investigations on the mode of action of a new antihypertensive drug, urapidil, in the isolated vas deferens |journal=Eur. J. Pharmacol. |volume=59 |pages=1–9 |year=1979 |doi= 10.1016/0014-2999(79)90018-9|url=|pmid=228944|issue=1–2}}</ref> this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum.<ref name="pmid6097380">{{cite journal |vauthors=((Verberne AJM)), Rand MJ |title=Pharmacological activities of the antihypertensive drug urapidil in the rat |journal=Clin. Exp. Pharmacol. Physiol. |volume=11 |pages=407–412 |year=1984 |doi= 10.1111/j.1440-1681.1984.tb00289.x|url= |pmid=6097380 |issue=4}}</ref> Unlike some other [[alpha-1 adrenoceptor|α<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonists]], urapidil does not elicit reflex tachycardia, and this may be related to its weak [[beta-1 adrenoceptor|β<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonist]] activity,<ref name="">{{cite book |vauthors=Schoetensack W, Bruckschen EG, Zech K |title=Urapidil |pages=19 |year=1983 |doi= |url= |work=New Drugs Annual: Cardiovascular Drugs}}</ref><ref name="pmid2984023">{{cite journal |vauthors=((Verberne AJM)), Rand MJ |title=Effect of urapidil on β-adrenoceptors of rat atria |journal=Eur. J. Pharmacol. |volume=108 |pages=193–196 |year=1985 |doi= 10.1016/0014-2999(85)90725-3|url= |pmid=2984023 |issue=2}}</ref> as well as its effect on cardiac vagal drive.<ref name="pmid1702490">{{cite journal |author=Ramage AG |title=Influence of 5-HT1A receptor agonists on sympathetic and parasympathetic nerve activity |journal=J. Cardiovasc. Pharmacol. |volume=15 |pages=S75–S85 |year=1990 |doi= |url= |pmid=1702490}}</ref> Urapidil is currently not approved by the [[Food and Drug Administration|U.S. Food and Drug Administration]], but it is available in [[Europe]].

== See also ==
* [[Naftopidil]]

== References ==
{{Reflist}}

{{Antihypertensives}}
{{Adrenergics}}
{{Serotonergics}}
{{Piperazines}}

[[Category:Chemical substances for emergency medicine]]
[[Category:Phenol ethers]]
[[Category:Piperazines]]
[[Category:Pyrimidines]]